Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Investing.com -- Artelo Biosciences Inc (NASDAQ:ARTL) stock surged 10% following the presentation of positive preclinical data for its lead fatty acid binding protein 5 (FABP5) inhibitor, ART26.12, in an osteoarthritis pain model.
The data, presented at the 35th Annual International Cannabinoid Research Society Symposium, showed that ART26.12 significantly alleviated pain associated with osteoarthritis in preclinical models. The non-opioid, non-steroidal analgesic drug candidate demonstrated efficacy comparable to naproxen, a commonly prescribed NSAID, while maintaining analgesic effectiveness throughout a four-week period of chronic dosing without developing tolerance.
Researchers observed that daily treatment with ART26.12 increased plasma levels of the endocannabinoids 2-Arachidonoylglycerol and Oleoylethanolamide, which were positively correlated with improved weight-bearing ability on the affected limb in the animal models.
The company highlighted that ART26.12 may offer safety advantages over NSAIDs, which are associated with gastrointestinal side effects in approximately one-third of patients and linked to a five-fold increase in gastric ulcer complications.
"These preclinical OA study results, which complement our recently announced positive human single dose safety data, continue to support ART26.12 as a well-differentiated and potentially safer alternative to NSAIDs in the treatment of osteoarthritis pain," said Professor Saoirse O’Sullivan, Vice President of Translation Sciences at Artelo.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.